Stelexis Therapeutics

stelexis is a deerfield founded and solely funded new york-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. deerfield founded stelexis therapeutics in 2017 together with scientific founders, drs. ulrich steidl, evripidis gavathiotis, amit verma and roman perez-soler of albert einstein college of medicine, montefiore medicine, new york and dr. derrick rossi of boston children’s hospital, harvard medical school.